We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
-8.24%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.72B
AUM Growth
-$153M
(-8.2%)
Cap. Flow
+$152M
Cap. Flow
% of AUM
8.83%
Top 10 Holdings %
Top 10 Hldgs %
73.79%
Holding
30
New
4
Increased
9
Reduced
2
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
THOR
Synthorx, Inc. Common Stock
THOR
|
+$141M |
| 2 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
+$72.2M |
| 3 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
+$26M |
| 4 |
Moderna
MRNA
|
+$24.9M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$20.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
+$110M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
+$49.6M |
| 3 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$19.4M |
| 4 |
PGNX
Progenics Pharmaceuticals Inc
PGNX
|
+$19M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Wave Life Sciences
WVE
$1.12B
| $316M | 18.38% |
7,512,049
| – | – |
|
2
Ascendis Pharma A/S
ASND
$16.5B
| $266M | 15.46% |
4,240,536
| – | – |
|
|
THOR
3
DELISTED
Synthorx, Inc. Common Stock
THOR
| $169M | 9.84% |
+9,724,598
| New | +$141M |
|
|
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
| $86.9M | 5.06% |
2,382,168
+503,400
| +27% | +$20.6M |
|
5
BioCryst Pharmaceuticals
BCRX
$2.42B
| $86M | 5.01% |
10,660,349
+1,425,657
| +15% | +$11.1M |
|
|
ORTX
6
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $76.2M | 4.44% |
+484,593
| New | +$72.2M |
|
7
InflaRx
IFRX
$243M
| $75.8M | 4.41% |
2,085,089
+117,241
| +6% | +$3.61M |
|
8
Solid Biosciences
SLDB
$792M
| $72.1M | 4.2% |
179,296
| – | – |
|
|
MYOV
9
DELISTED
Myovant Sciences Ltd.
MYOV
| $60.9M | 3.55% |
3,711,549
+259,690
| +8% | +$5.12M |
|
|
EIDX
10
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $59.2M | 3.45% |
2,162,671
| – | – |
|
11
Crinetics Pharmaceuticals
CRNX
$8.88B
| $56.2M | 3.27% |
1,875,209
+174,192
| +10% | +$4.9M |
|
12
Rhythm Pharmaceuticals
RYTM
$7.31B
| $52.4M | 3.05% |
1,950,332
| – | – |
|
|
IMMU
13
DELISTED
Immunomedics Inc
IMMU
| $43.1M | 2.51% |
3,021,466
-98,312
| -3% | -$1.95M |
|
14
Arvinas
ARVN
$530M
| $40.3M | 2.35% |
3,138,412
| – | – |
|
|
RARX
15
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $34M | 1.98% |
4,858,260
+1,006,452
| +26% | +$15.8M |
|
16
TG Therapeutics
TGTX
$8.19B
| $33.6M | 1.96% |
8,198,337
| – | – |
|
|
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
| $28.5M | 1.66% |
1,441,070
| – | – |
|
|
MNTA
18
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $28.2M | 1.64% |
2,558,357
+1,000,000
| +64% | +$13.9M |
|
|
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $26.3M | 1.53% |
2,456,669
-1,476,820
| -38% | -$19.4M |
|
|
EIGR
20
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $24.5M | 1.43% |
+80,515
| New | +$26M |
|
21
Iovance Biotherapeutics
IOVA
$2.04B
| $24.1M | 1.4% |
2,720,452
+1,599,299
| +143% | +$15.4M |
|
|
22
Moderna
MRNA
$21.6B
| $23.1M | 1.35% |
+1,514,326
| New | +$24.9M |
|
23
KALA BIO
KALA
$12.5M
| $22.2M | 1.29% |
1,817
+971
| +115% | +$16.8M |
|
|
SCPH
24
DELISTED
scPharmaceuticals
SCPH
| $10.7M | 0.63% |
2,857,143
| – | – |
|
25
Protara Therapeutics
TARA
$214M
| $3.04M | 0.18% |
33,437
| – | – |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q4 2018 Portfolio in Review
As of Q4 2018, RA Capital Management held 30 positions worth $1.72B, down 8.2% from $1.87B the previous quarter. Its ten largest holdings account for 74% of the portfolio.
RA Capital Management deployed $152M of net new capital in Q4 2018, opening 4 new positions and adding to 9 existing holdings. Its largest new stake was Synthorx, Inc. Common Stock: 9,724,598 shares worth $169M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier.
On the sell side, the largest reduction was Dicerna Pharmaceuticals, Inc., an estimated $19.4M trimmed.
- RA Capital Management's largest Q4 2018 buy was Synthorx, Inc. Common Stock: 9,724,598 shares worth $169M.
- RA Capital Management added most to Zogenix, Inc. in Q4 2018, an estimated $20.6M increase.
- RA Capital Management's biggest Q4 2018 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $19.4M.
- RA Capital Management fully exited Endocyte, Inc. Common Stock in Q4 2018, selling an estimated $110M.
- RA Capital Management's ten largest holdings make up 74% of its $1.72B portfolio in Q4 2018.
- RA Capital Management opened 4 new positions and closed 5 in Q4 2018.
- RA Capital Management's portfolio value fell 8.2% quarter-over-quarter to $1.72B.
Based on RA Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.